Dany's BienenWohl

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

oxalsýru tvíhýdrat

Available from:

Dany Bienenwohl GmbH

ATC code:

QP53AG03

INN (International Name):

oxalic acid dihydrate

Therapeutic group:

Honey bees

Therapeutic area:

Ectoparasiticides for topical use, incl. insecticides, Ectoparaciticides, insecticides and repellents

Therapeutic indications:

Fyrir meðferð varroosis (Varroa anti -) af býflugur hunang (Api mellifera) í ungum-frjáls nýlendur.

Authorization status:

Leyfilegt

Authorization date:

2018-06-14

Patient Information leaflet

                                B. FYLGISEÐILL
19
FYLGISEÐILL:
DANY’S BIENENWOHL DUFT OG LAUSN FYRIR
39,4 mg/ml BÝBÚSÖRDREIFU FYRIR HUNANGSBÝ
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi:
Dany Bienenwohl GmbH
Geyerspergerstr. 27
80689 Munich
Þýskaland
Framleiðandi sem ber ábyrgð á lokasamþykkt:
Wirtschaftsgenossenschaft deutscher Tierärzte (WDT) eG
Siemensstraße 14
30827 Garbsen
Þýskaland
2.
HEITI DÝRALYFS
Dany’s BienenWohl duft og lausn fyrir 39,4 mg/ml býbúsördreifu
fyrir hunangsbý
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
Eitt
GLAS MEÐ 375 G AF LAUSN
inniheldur:
VIRKT INNIHALDSEFNI:
Oxalsýrutvíhýdrat 17,5 g (jafngildir 12,5 g af oxalsýru)
Tær og litlaus lausn.
Eitt
GLAS MEÐ 750 G AF LAUSN
inniheldur:
VIRKT INNIHALDSEFNI:
Oxalsýrutvíhýdrat 35,0 g (jafngildir 25,0 g af oxalsýru)
Tær og litlaus lausn.
Einn
SKAMMTAPOKI MEÐ 125 G AF DUFTI
inniheldur:
HJÁLPAREFNI:
Súkrósi 125 g
1 ml af
BLANDAÐRI BÝBÚSÖRDREIFU
inniheldur:
VIRKT INNIHALDSEFNI:
Oxalsýrutvíhýdrat 39,4 mg (jafngildir 28,1 mg af oxalsýru)
Litlaus, tær til svolítið gruggug dreifa.
4.
ÁBENDING(AR)
Til meðferðar á varróaveiki (
_Varroa destructor)_
hjá hunangsbýi
(
_Apis mellifera),_
í búum án
ungviðis.
20
5.
FRÁBENDINGAR
Engar.
6.
AUKAVERKANIR
Í klínískum rannsóknum var mjög algengt að aukin dánartíðni
kæmi fram. Þetta hafði ekki áhrif á
langtímaþróun búa.
Tíðni aukaverkana er skilgreind á eftirfarandi hátt:
- Mjög algengar (aukaverkanir koma fyrir hjá fleiri en 1 af hverjum
10 búum sem fá meðferð)
- Algengar (koma fyrir hjá fleiri en 1 en færri en 10 af hverjum 100
búum sem fá meðferð)
- Sjaldgæfar (koma fyrir hjá fleiri en 1 en færri en 10 af hverjum
1.000 búum sem fá meðferð)
- Mjög sjaldgæfar (koma fyrir hjá fleiri en 1 en færri en 10 af
hverjum 10.000 búum sem fá meðferð)
- Koma örsjaldan fyrir (koma fyrir hjá færri en 1 af hverjum 10.000
búum sem fá meðferð, þ.m.t.
einstö
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
1
1.
HEITI DÝRALYFS
Dany’s BienenWohl duft og lausn fyrir 39,4 mg/ml býbúsördreifu
fyrir hunangsbý
2.
INNIHALDSLÝSING
Eitt
GLAS MEÐ 375 G AF LAUSN
inniheldur:
VIRKT INNIHALDSEFNI:
Oxalsýrutvíhýdrat 17,5 g (jafngildir 12,5 g af oxalsýru)
HJÁLPAREFNI:
Sjá lista yfir öll hjálparefni í kafla 6.1.
Eitt
GLAS MEÐ 750 G AF LAUSN
inniheldur:
VIRKT INNIHALDSEFNI:
Oxalsýrutvíhýdrat 35,0 g (jafngildir 25,0 g af oxalsýru)
HJÁLPAREFNI:
Sjá lista yfir öll hjálparefni í kafla 6.1.
Einn
SKAMMTAPOKI MEÐ 125 G AF DUFTI
inniheldur:
HJÁLPAREFNI:
Súkrósi 125 g
Sjá lista yfir öll hjálparefni í kafla 6.1.
1 ml af
BLANDAÐRI BÝBÚSÖRDREIFU
inniheldur:
VIRKT INNIHALDSEFNI:
Oxalsýrutvíhýdrat 39,4 mg (jafngildir 28,1 mg af oxalsýru)
HJÁLPAREFNI:
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Duft og lausn fyrir býbúsördreifu.
Lausn fyrir býbúsördreifu (glas sem inniheldur virka efnið):
Tær og litlaus lausn.
Duft fyrir býbúsördreifu (skammtapoki):
Hvítt kristallað duft.
4.
KLÍNÍSKAR UPPLÝSINGAR
4.1
DÝRATEGUNDIR
Hunangsbý (
_Apis mellifera) _
4.2
ÁBENDINGAR FYRIR TILGREINDAR DÝRATEGUNDIR
Til meðferðar á varróaveiki (
_Varroa destructor)_
hjá hunangsbýi
(
_Apis mellifera),_
í búum án
ungviðis.
2
4.3
FRÁBENDINGAR
Engar.
4.4
SÉRSTÖK VARNAÐARORÐ FYRIR HVERJA DÝRATEGUND
Dany’s BienenWohl má aðeins nota einu sinni í búum án
ungviðis.
Dýralyfið skal nota sem þátt í heildrænni áætlun gegn
varróaveiki ásamt reglulegu eftirliti með
mítlafjölda í fallgildrum. Ef mögulegt er skal nota til skiptis
þetta dýralyf og annan samþykktan
varróaeyði með annan verkunarhátt til að minnka líkur á
ónæmismyndun hjá varróamítlum.
4.5
SÉRSTAKAR VARÚÐARREGLUR VIÐ NOTKUN
Sérstakar varúðarreglur við notkun hjá dýrum
Ekki nota stærri skammt en ráðlagt er og ekki nota dýralyfið
oftar en einu sinni. Býflugur þola illa
endurteknar meðferðir. Ef hver kynslóð af þernum er meðhöndluð
of
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-07-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-07-2018
Public Assessment Report Public Assessment Report Bulgarian 17-07-2018
Patient Information leaflet Patient Information leaflet Spanish 17-07-2018
Public Assessment Report Public Assessment Report Spanish 17-07-2018
Patient Information leaflet Patient Information leaflet Czech 17-07-2018
Public Assessment Report Public Assessment Report Czech 17-07-2018
Patient Information leaflet Patient Information leaflet Danish 17-07-2018
Public Assessment Report Public Assessment Report Danish 17-07-2018
Patient Information leaflet Patient Information leaflet German 17-07-2018
Public Assessment Report Public Assessment Report German 17-07-2018
Patient Information leaflet Patient Information leaflet Estonian 17-07-2018
Public Assessment Report Public Assessment Report Estonian 17-07-2018
Patient Information leaflet Patient Information leaflet Greek 17-07-2018
Public Assessment Report Public Assessment Report Greek 17-07-2018
Patient Information leaflet Patient Information leaflet English 17-07-2018
Public Assessment Report Public Assessment Report English 17-07-2018
Patient Information leaflet Patient Information leaflet French 17-07-2018
Public Assessment Report Public Assessment Report French 17-07-2018
Patient Information leaflet Patient Information leaflet Italian 17-07-2018
Public Assessment Report Public Assessment Report Italian 17-07-2018
Patient Information leaflet Patient Information leaflet Latvian 17-07-2018
Public Assessment Report Public Assessment Report Latvian 17-07-2018
Patient Information leaflet Patient Information leaflet Lithuanian 17-07-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-07-2018
Public Assessment Report Public Assessment Report Lithuanian 17-07-2018
Patient Information leaflet Patient Information leaflet Hungarian 17-07-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 17-07-2018
Public Assessment Report Public Assessment Report Hungarian 17-07-2018
Patient Information leaflet Patient Information leaflet Maltese 17-07-2018
Public Assessment Report Public Assessment Report Maltese 17-07-2018
Patient Information leaflet Patient Information leaflet Dutch 17-07-2018
Public Assessment Report Public Assessment Report Dutch 17-07-2018
Patient Information leaflet Patient Information leaflet Polish 17-07-2018
Public Assessment Report Public Assessment Report Polish 17-07-2018
Patient Information leaflet Patient Information leaflet Portuguese 17-07-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 17-07-2018
Public Assessment Report Public Assessment Report Portuguese 17-07-2018
Patient Information leaflet Patient Information leaflet Romanian 17-07-2018
Public Assessment Report Public Assessment Report Romanian 17-07-2018
Patient Information leaflet Patient Information leaflet Slovak 17-07-2018
Public Assessment Report Public Assessment Report Slovak 17-07-2018
Patient Information leaflet Patient Information leaflet Slovenian 17-07-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 17-07-2018
Public Assessment Report Public Assessment Report Slovenian 17-07-2018
Patient Information leaflet Patient Information leaflet Finnish 17-07-2018
Public Assessment Report Public Assessment Report Finnish 17-07-2018
Patient Information leaflet Patient Information leaflet Swedish 17-07-2018
Public Assessment Report Public Assessment Report Swedish 17-07-2018
Patient Information leaflet Patient Information leaflet Norwegian 17-07-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 17-07-2018
Patient Information leaflet Patient Information leaflet Croatian 17-07-2018
Public Assessment Report Public Assessment Report Croatian 17-07-2018